KARACHI: A local pharmaceutical company has reached an agreement with an American company for the manufacturing of HIV drugs.

The stock's fall snapped a five-day winning streak.

The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.74 which represents a slight increase of $0.80 or 0.95% from the prior close of $83.94. The stock opened at ...

An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment ...

Gilead Sciences GILD has entered into licensing deals with six pharmaceutical companies to manufacture and supply a cheaper ...

Surprise: Hannah and I switched Slog days. Because I respect tradition, we’ll begin with the weather, which is quite nice ...

Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical ...

Europe has announced a €2 million project to research long COVID, following €100 million already invested since 2021. Is all ...

The decision to allow generic versions of lenacapavir, which would go to countries with the highest rates of infection, has the potential to bring about an end to the HIV pandemic.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...